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Abstract
Immunotherapy for B-cell chronic lymphocytic leukaemia (B-CLL) and other haematological
malignancies may consist of passive antibody, active immunization or adoptive T-cell transfer. This
chapter will focus on T-lymphocyte immunotherapy; an approach supported by earlier observations
that the beneficial effects of allogeneic stem cell transplantation depend, in part, on the graft-versus-
leukaemia effects mediated by these cells. One promising strategy consists of the genetic
manipulation of effector T lymphocytes to express tumour-specific T-cell receptors or chimeric
antigen receptors directed against surface antigens on the B-CLL cells. This methodology is now
being integrated with the concept that tumour recurrence may be due to the persistence of a reservoir
of more primitive and chemoresistant tumour cells, dubbed ‘cancer stem cells’, with self-renewal
capacity. Identification and characterization of these cancer stem cells in B-CLL is crucial for the
development of new anti-tumour agents, and for the identification of target antigens for cellular
immunotherapy. This chapter will describe how immunotherapy may be directed to a more primitive
side population of B-CLL cells.
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B-cell chronic lymphocytic leukaemia (B-CLL) is the most frequently diagnosed form of
leukaemia in the Western world.1 In more than 95% of patients, it is characterized by the clonal
expansion of a small B-lymphocyte subset that co-expresses the CD5 surface marker distinct
from most other peripheral blood B cells.2 The clinical course of the disease is generally
indolent, although several biological and clinical prognostic factors identify patients with more
aggressive disease.1,3,4 Early-stage B-CLL requires minimal intervention, but malignant
lymphocytes accumulate progressively in lymph nodes, liver and spleen, and bone marrow
failure may ultimately occur. Small molecule therapeutics such as fludarabine may diminish
disease levels but overall survival is not prolonged significantly.5 Similarly, passive
immunotherapy with B-cell-specific monoclonal antibodies may modify immediate symptoms
and signs, but does not lead to long-term disease-free survival.6,7 More aggressive treatment
with allogeneic stem cell transplantation (allo-SCT) may eradicate the disease8, but even with
subablative preparative regimens, transplant-related mortality remains significant, particularly
in the older age group who are most commonly afflicted with the disease.9
The anti-leukaemia activity of allo-SCT is only partially a consequence of the intensive
chemotherapy or radiotherapy used as a preparative regimen. In addition, the donor T-cell
component of the graft likely contributes a significant graft-versus-leukaemia (GvL) effect.9,
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10 Unfortunately, this benefit is frequently associated with more generalized donor T-cell
alloreactivity, causing graft-versus-host disease (GvHD) with considerable morbidity and
mortality.8 Nevertheless, the presence of the GvL effect in patients with B-CLL undergoing
allo-SCT implies that these cells may be targeted effectively by effector T cells. Strategies that
selectively amplify T cells that recognize tumour-specific antigens may produce therapeutic
benefit without the adverse effects of more generalized alloreactivity.
Target Antigens for Adoptive T-Cell Immunotherapy of B-CLL
B-CLL cells may express or overexpress a number of tumour-associated antigens (TAAs) that
can be the target of specific cytotoxic T-lymphocyte (CTL) responses.11–13 These include
fibromodulin, MDM2 (murine double minute 2), survivin, oncofetal antigen-immature laminin
receptor protein (OFAiLRP), KW-2 and KW-13 (identified by serological screening of cDNA
expression libraries or SEREX), preferentially expressed antigen of melanoma (PRAME) and
receptor for hyaluronic-acid-mediated motility (RHAMM/CD168).11 While these TAAs are
expressed, often at high levels, by B-CLL cells, they are absent from most normal host tissues.
B-CLL cells also express a unique monoclonal immunoglobulin, so the idiotypic determinants
on this molecule may serve as true tumour-specific antigenic targets.11
CD8+ and CD4+ T lymphocytes that recognize TAAs can be identified and isolated from B-
CLL patients and healthy donors.12 However, TAAs are often poorly immunogenic and TAA-
specific CTLs are rare and usually have low affinity for the antigen.14 Moreover, tumour-
specific CTLs in cancer patients may be anergic due to the inhibitory effects of the tumour
micro-environment15, or poorly functional as a consequence of extensive chemotherapy/
radiation treatment. The generation of sufficient numbers of functionally potent TAA-specific
CTLs for clinical trials remains challenging.
To overcome the limitation of isolating and expanding TAA-specific CTLs, it may be possible
to combine this approach with active immunotherapy using gene-modified cancer vaccines.
16 For example, immunization prior to preparation of TAA-CTL should increase precursor
frequency and simplify the process of CTL generation, while a vaccine boost following the
adoptive transfer of the cells could further increase their in-vivo persistence and frequency.
Vaccination with B-CLL tumour cells engineered to express CD40L certainly induces CLL-
specific CD4+ and CD8+ T-cell immune responses17,18, and if the logistical and regulatory
impediments associated with such an approach can be overcome, this combination of active
and passive immunotherapy may be of considerable value.
An alternative strategy is to use gene transfer to generate large numbers of T cells with defined
anti-tumour specificity. Two technologies currently being studied for this purpose are the
transfer of genes encoding a T-cell receptor (TCR) or a chimeric antigen receptor (CAR).
αβTCR Gene Transfer
The antigen specificity of T lymphocytes is determined by the expression of a ‘unique’ TCR,
composed of α- and β-chains, which recognizes a specific protein-derived peptide presented
in the context of major histocompatibilty complex (MHC) class I and class II molecules for
CD8+ cells and CD4+ cells, respectively. Polyclonal T lymphocytes can be manipulated
genetically to express transgenic TCR-α and TCR-β chains, specific for a peptide derived from
a tumour antigen.19 Moreover, transgenic T cells are biologically functional since they can
specifically eliminate tumour cells expressing the tumour antigen recognized by the transgenic
TCR.19,20 Since B-CLL cells express several TAAs that are known to be processed and
presented in the context of MHC molecules, TCR gene transfer may represent a valuable
immunotherapy strategy.
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The recent clinical translation of TCR gene transfer has been made possible by significant
technical improvements in retroviral vector construction allowing for the co-expression of
multiple genes, packaging cell lines, and protocols for optimizing primary T-cell transduction.
Recently, feasibility of TCR gene transfer was demonstrated in a clinical study for melanoma
patients.19 Investigators at the National Cancer Institute demonstrated that adoptive transfer
of polyclonal T cells transduced with a retroviral vector encoding the TCR-α and TCR-β chains
of a MART1-specific TCR induced an objective clinical response in two of 15 melanoma
patients.19 In demonstrating the therapeutic potential of TCR gene transfer, the study offered
potential strategies to optimize T-cell transduction. For example, TCR-α and TCR-β chains
need to be coupled with CD3-associated molecules to be expressed on the cell surface, and
free TCR-α and TCR-β chains are degraded rapidly. Transgenic TCRs have to compete with
the native TCRs for CD3 binding, and the low availability of free CD3 molecules may
significantly impair transgenic TCR receptor expression on the cell surface. Moreover,
transgenic TCR-α and TCR-β chains may form heterodimers with native TCRs, not only further
impairing the formation of the desired transgenic TCR, but also producing TCRs with unknown
antigen specificity and potential autoreactivity.20,21
In the clinical trial described by Morgan et al, both the above concerns did not occur, since the
transgenic MART-1-specific TCR was biologically functional and auto-immunity was not
evident in the treated patients, albeit after relatively short follow-up.19 However, these
observations may not be applicable to other tumour models, and additional studies are in
progress to identify anti-tumour TCR clones with high affinity/avidity for TAAs in which the
transgenic TCR is modified to reduce the risk of cross-pairing and the formation of
heterodimers (Figure 1a).22,23
Despite these encouraging results, two additional barriers limit the broad clinical application
of this strategy. First, the specificity of the TCR is restricted by HLA molecules so that multiple
receptors must be generated to cover common MHC polymorphisms. Although, in theory, a
limited number of receptors may be sufficient to include more than 90% of the European
Caucasian population21, this would still require a massive effort of TCR cloning and validation
in clinical trials. Secondly, tumour cells may escape T-cell recognition by downregulating
MHC molecules or mutating/deleting the antigenic epitopes specifically recognized by the
TCR.24,25 The risk of selecting tumour deletion-mutants may be reduced by treating patients
in a state of minimal residual disease after tumour debulking by conventional means, or by
targeting antigens essential for maintaining the neoplastic phenotype. In addition, the
combination of T-cell therapy with therapeutic agents that upregulate MHC expression in
tumour cells may also reduce the risk of tumour escape.
Although the TCR gene transfer approach has not been tested in B-CLL, the promising results
obtained in preclinical evaluation26 suggest that this strategy could also be applied to antigens
expressed in B-CLL such as PRAME and survivin.
Chimeric Antigen Receptor Gene Transfer
An alternative strategy for TCR transfer is the construction and transfer of genes encoding a
chimeric antigen receptor into the T cells. CARs are artificial molecules usually composed of
a specific-antigen-binding portion made of the variable domains of the heavy chain and light
chain of a monoclonal antibody, linked together as a single-chain Fv antibody (scFv). To this
is coupled a signalling region from either the ζ-chain of the TCR/CD3 complex or the γ-chain
of the Fc∈RI receptor (Figure 1b).27,28 When expressed in T cells, CARs bind the antigen
expressed on the cell surface of the target tumour cells through the scFv component, and trigger
T-cell effector function through the FcR-γ or CD3-ζ domain.27,28
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The major advantage of CAR gene transfer over TCR gene transfer is that recognition is MHC
independent, since native molecules are recognized rather than processed proteins. Moreover,
recognition can be extended to non-protein surface molecules, which are outside the scope of
recognition of the conventional αβ-TCR.29 Conversely, since most CARs are antibody derived,
they can only recognize TAAs that are present on the cell surface, and unlike αβ-TCR, they
cannot recognize ‘internal’ TAA targets that are nonetheless processed and presented by MHC
molecules to the αβ-TCR.
B-CLL is particularly suited to attack by CAR expressing T cells, since there are several
suitable TAAs that have been clinically validated, such as CD206, that may be targeted using
specific monoclonal antibodies (Mabs). One might argue that since Mabs directed to these
antigens fail to eliminate disease, T cells directed to the same target by a CAR will be similarly
ineffectual. However, T cells exhibit multiple pathways for cell-mediated killing of tumour
cells, can actively traffic to tumour sites, and can persist as memory cells.30 As such, T cells
targeted to TAAs such as CD20 may be more effective than Mabs in generating durable tumour
responses, even when their specificity is the same as the Mabs.
CD20 and CD19 antigens appear in the early phase of B-cell development, and are almost
invariably expressed at high levels on B-CLL cells.1 T lymphocytes expressing transgenic
CARs directed to CD19 or CD20 were highly effective at eliminating B-cell-derived
malignancies in animal models31–34, indicating that this strategy may have potential clinical
benefits. CARs expressing T cells mediate their cytolytic effect through expression of perforin/
granzyme-B and significant release of interferon-γ. One potential drawback of targeting CD20
or CD19 using CAR-modified T cells could be the extensive and prolonged elimination of the
normal B-lymphocyte compartment and consequent impairment of humoral immunity.
Although this side effect may often be clinically manageable by using human immunoglobulin
infusion, a preferable target would be an antigen expressed more selectively by B-CLL cells,
which would then allow preservation of humoral immunity. One possibility is to target the κ-
or λ-light chain of human immunoglobulin, which is clonally expressed on B-CLL cells and
other mature B-cell-derived malignancies. Hence, all κ+ (or λ+) B-CLL and normal B cells
could be eliminated, whilst sparing the normal B-cell population expressing the reciprocal light
chain (Figure 2).35 Animal studies have shown that excellent disease protection is afforded
provided that B cells expressing either κ or λ Ig are retained.35,36 Finally, CD23, which is
overexpressed in B-CLL cells and only weakly expressed on normal B cells, may be suitable
as a target.1
Despite the clinical potential of CAR gene transfer, early clinical trials using CAR-redirected
polyclonal T cells (including CAR-CD19-redirected cells) in patients with human
immunodeficiency virus or cancer37–40 did not show evidence of clinical response. In part,
lack of clinical benefit may be attributed to the limited persistence of CAR-redirected T cells
after adoptive transfer.38,39 In addition, effective T-cell activation requires the presence of
multiple co-stimulatory signals which undergo ligation in conjunction with the engagement of
the antigen-specific receptor. In the absence of such co-stimulation, the response is aborted
and T cells may become anergic. The majority of target tumour cells lack expression of ligands
for the critical co-stimulatory molecule receptors on T cells, and since CAR molecules coupled
only to the CD3-ζ domain can themselves provide just one signal to T lymphocytes following
target antigen engagement, T-cell activation is incomplete. Hence, ‘second-generation CARs’
have been constructed in which the CD3-ζ domain has been combined in cis with specific
endodomains derived from different co-stimulatory molecules including CD28, ICOS, CD134
or CD137 (Figure 1b).23,35,41–43 When T cells expressing these new constructs encounter
tumour-target antigens with their CAR, they receive both CD3-ζ and co-stimulatory domain
signals, and produce cytokines such as interleukin (IL)-2 that enhance their expansion, function
and persistence. Like other tumours, B-CLL cells lack expression of most co-stimulatory
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molecules, and clinical studies testing CD19- and CD20-specific CARs coupled to the CD28
endodomain are now in progress.
T-Cell Manipulation in Patients with B-CLL
Genetic modification of T cells from B-CLL patients may be technically problematic. B-CLL
cells secrete a high level of immunomodulatory factors, including tumour growth factor-β and
IL-10, that generate an immunosuppressive tumour environment.15 As a consequence, T
lymphocytes in patient peripheral blood are often functionally defective and contain a high
proportion of cells with regulatory phenotype (CD4+/CD25+/FoxP3+) and function.18 These
Treg can also impair the function of genetically modified T cells.44 Fortunately, second-
generation CARs, which include the CD28 co-stimulatory endodomain, are resistant to the
inhibitory effects of Treg cells.44 The molecular mechanisms underlying this resistance still
need to be elucidated. T lymphocytes isolated from the peripheral blood of B-CLL patients can
be manipulated genetically to express CAR molecules (CAR-CD19-CD28 or CAR-κ-light
chain-CD28) and to acquire cytotoxic activity against autologous tumour cells (Figure 2).35
Clinical trials will determine whether these cells remain functionally active after adoptive
transfer even in an immunosuppressive tumour environment of B-CLL patients. In these trials,
B-CLL patients will be infused with autologous T cells genetically modified to express CAR-
CD19 or CAR-κ-light chain. Dose escalation will be used in a phase I study, in which patients
will receive 2 × 107/m2, 1 × 108/m2 or 2 × 108/m2 cells in one single dose, and safety, persistence
of adoptively transferred T cells, and effects on the leukaemic and normal B lymphocytes will
be evaluated. If detrimental effects from the B-CLL cells are discovered, adoptive transfer of
CAR-redirected T cells could be combined with conventional treatment to minimize tumour
burden or Treg numbers45, and the CAR T cells themselves may be modified to counteract
tumour inhibitory factors such as tumour growth factor-β.46
Cancer Stem/Progenitor Cells and B-CLL
Almost all malignancies contain cells that are heterogeneous in phenotype and proliferative
potential. Recently, the concept of ‘cancer stem cells’ (or progenitor or tumour-initiating/
repopulating cells) has been elevated in its importance because of their apparent role in
tumourigenesis, drug resistance and relapse. In haematological malignancies, there is
compelling evidence for the presence of cancer stem cells, since differences in proliferative
potential between defined subsets can be readily observed in vitro using colony forming
assays47, and in vivo by engraftment studies in immuno-deficient mice (NOD/SCID).48 These
and other studies show that only a fraction of tumour cells are able to reinitiate tumour colonies.
49 As tumour subpopulations based on phenotypic markers (e.g. CD34+CD28− in acute
myeloid leukaemia) or functional characteristics [e.g. Hoechst 33342 side population (SP) and
aldehyde dehydrogenase activity] can reconstitute a heterogeneous cancer, many tumours may
possess self-renewal and differentiation programmes that are similar to normal adult stem cells.
49 The distinction between cancer stem cells (self-renew and differentiate) and cancer
progenitor cells (differentiate but do not self-renew) is often not made clear in studies of this
putative phenomenon. However, for the purposes of targeted therapy, the term can be defined
operationally: a cancer stem cell is a cancer cell whose eradication leads to the subsequent and
progressive regression of the remaining non-stem-cell tumour.
Is there a B-CLL Proliferative Compartment?
B-CLL has long been considered a disease of ‘accumulation’ of anergic B cells which are
defective for apoptosis or programmed cell death.50,51 B-CLL tumour cells overexpress several
anti-apoptosis genes, including Bcl-252,53 and Mcl-154, supporting the notion that this form of
chronic leukaemia is the result of the abnormal lifespan of malignant B cells. In addition, B-
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CLL tumour cells are hyporesponsive to polyclonal B-cell stimuli compared with normal B
cells55, setting the B-CLL disease course apart from the uncontrolled proliferation which
characterizes many forms of acute leukaemia.
Recently, there has been a change in perspective in which both accumulation (resistance to
death) and proliferation (growth) contribute to the pathobiology of B-CLL.56 This shift has
been driven by the importance of ‘proliferative centres’ in the lymphoid organs of B-CLL
patients, and the identification of new cell survival and activation signals in these malignant
B cells. B-CLL tumour cells in the peripheral blood rarely progress through the cell cycle.57,
58 In contrast, focal aggregates of proliferating tumour cells (so-called ‘pseudo-follicles’) can
be found in the lymph nodes and bone marrow of many B-CLL patients. Granziero et al
demonstrated that these pseudo-follicles contained B-CLL tumour cells expressing the cell
cycle marker Ki-67 and survivin, a member of the inhibitor of apoptosis family.13 Proliferation
of B-CLL in lymph nodes may be mediated by environmental stimuli, including ligation of
CD40 on B-CLL cells by CD40L (CD154) on activated CD4+T lymphocytes.13 Studies that
measure birth and death rates of B-CLL by labelling DNA of dividing cells56,59,60 using
deuterium (2H) have shown that B-CLL cells are newly generated at rates similar to or even
greater than normal B cells.60 However, not all B-CLL tumour cells proliferate at equal rates.
CD5+CD19+CD38+ cells incorporate higher levels of 2H than CD38− cells, and in addition,
the CD38+ subset co-express markers of activation and proliferation including CD69, CD62L,
ZAP-70 and Ki-67.61 Given that peripheral blood B-CLL expresses high levels of p27 (also
called ‘cyclin-dependent kinase 1 B’ or ‘Kip1’)62, and that lymph nodes and bone marrow
appear to contain proliferating tumour cells, it seems likely that the cells found in the lymphoid
compartment contribute to the accumulation of B-CLL observed in the peripheral blood, and
that targeting this small fraction of proliferating tumour cells may produce longer-term
remission.56,63
Is there a B-CLL Stem Cell Compartment?
B-CLL manifests a heterogenic phenotype in which cells exhibit diverse levels of
responsiveness to chemotherapy. To date, however, identification of the subpopulation
responsible for drug resistance and relapse has proven elusive. One means of linking stem cell
properties with cytotoxic drug resistance is the identification of an SP of cells on fluorescence
flow cytometry by means of their capacity to efflux vital dyes.64 Over the past several years,
a primitive SP cell subset with marrow repopulating ability has been defined in normal bone
marrow from many mammals, including humans, using the fluorescent dyes Rhodamine 123
and Hoechst 33342.64,65 For example, SP cells obtained from normal marrow have a
CD34low/neg phenotype and can repopulate lethally irradiated mice in serial transplantation
models.64 The association between the SP phenotype and progenitor/stem cell enrichment has
been supported in a variety of tissues in addition to bone marrow, including skeletal muscle,
liver, brain, mammary, kidney, skin, testis and retinal tissue.66 Due to this wide biological
distribution of SP cells, the present authors and others reasoned that malignancies might also
harbour SP cells with tumour stem cell properties. The intrinsic dye efflux capacity of these
cells should be associated with rapid expulsion of many cytotoxic drugs, perhaps allowing the
cells to survive treatment and produce relapse.
The present authors initially reported a malignant CD45+CD34low/neg SP cell subset in more
than 80% of patients with acute myeloid leukaemia.67 These cells generated CD45+CD34+
malignant haematopoietic progenitor cells functioning as leukaemic stem cells. As the cells
also expelled lipophilic antileukaemic drugs, the data suggested that the SP subset is capable
of contributing to relapse.67 The authors also found malignant SP cells in solid tumours, such
as neuroblastoma68, in which 15 of 23 primary neuroblastomas contained
CD45−CD71−GD2+ SP cells. Although the authors could not precisely assign a position to SP
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cells in the developmental hierarchy of neuroblastoma malignancy, the phenotypic
characteristics of the SP subset, such as high expression of GD2 and stem cell factor receptor,
together with their greater replicative potential in cell culture and high expression of two
transporter proteins, ABCA3 and ABCG2, are all consistent with proximity to an early cell in
the hierarchy of neural crest progenitor development. Other groups have now reported SP cells
in additional solid tumours, including gliomas69, hepatocellular carcinoma70 and breast cancer.
71,72 Importantly, these studies indicate that the SP subset is enriched for tumourigenic cells
(i.e. cells that have the capacity to form new tumours in vitro and in vivo), supporting the
hypothesis that cancer stem cells/progenitor cells play an important role in tumourigenesis.
As anticipated from the above results, SP cells are readily found in many other haematological
malignancies, including multiple myeloma73 and adult T-cell leukaemia/lymphoma.74 The SP
phenotype is again associated with resistance to anti-neoplastic agents.73 The present authors
have since examined B-CLL primary tumour samples for the presence of SP cells, and found
0.1–2% SP cells amongst the circulating CD5+CD19+ B-CLL cells in 12 of 15 (80%) patients
studied (Figure 3), suggesting that in this disease there is a phenotypically defined
subpopulation that may contribute to disease resistance. Overall, the evidence that SP cells
exist in both haematological and non-haematological tumours, and are enriched for tumour-
initiating cells and resistant to chemotherapy, indicates that targeting this population in B-CLL
may be critical in order to eradicate the disease.
Targeted Immunotherapy for B-CLL ‘Stem Cell’ Compartments
As described above, effector T cells can, in principle, be used to eradicate malignancies30,75–
78, but this approach can only work if the T cells target antigens present on any putative stem
cell subset. B-CLL cells express many TAAs, including RHAMM/CD168, fibromodulin,
PRAME and PANE1.79,80 Since cancer stem cells differ phenotypically from bulk tumour
cells, it is critical that the target antigens are expressed on cancer stem cells, and desirable that
they should be critical to the maintenance of the malignancy. Targeting the antigens expressed
on both leukaemia stem cells and ‘mature’ leukaemic blasts has been shown to be feasible
using CTLs specific for minor histocompatibility antigens (mHags).81,82 In acute myeloid
leukaemia, for example, mHag-specific CTLs recognize the stem cell compartment
(CD34+CD38−) and prevent engraftment and disease.48,82 Antigens that are overexpressed in
drug-resistant (SP) cancer stem cells can also be exploited as CTL targets. Polycomb group
genes such as Bmi-1 and EZH2 are recognized by tumour infiltrating lymphocytes and in-vitro-
generated CTLs.83 Bmi-1 contributes to self-renewal and regulating proliferative activity in
normal stem and progenitor cells84,85, while EZH2 is necessary for cellular proliferation86, so
target antigens may well meet the dual criteria of being present in the malignant stem cell and
essential for its survival and expansion. There are concerns, however, that these antigens are
also expressed in the normal stem cell compartment and that targeting them may produce severe
toxicity.
Since B-CLL also contains a phenotypically distinct putative stem cell population, this too may
be targeted by immune mechanisms. The authors are currently identifying and validating
potential target antigens for CTLs. Of note, it may be possible to use the bulk B-CLL population
as a ‘surrogate’ stimulator to generate a specific anti-SP cell response. One of the observations
made in vaccine studies using CD40-activated B-CLL cells as the immunogen is that the
activated B-CLL cells not only upregulate the co-stimulatory molecules CD80 and CD8612,
16,87–89 and dramatically increase the ability of the B-CLL cells to recruit T-cell
responses13, but also increase their expression of potential target antigens such as survivin and
p53.90 These antigens are also highly expressed in B-CLL SP cells, but not in the unstimulated
bulk B-CLL population. Hence a combination of adoptive immunotherapy with T cells and
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booster vaccinations with CD40-activated B-CLL cells may ensure effective and sustained
targeting of antigens expressed in the putative stem cells of B-CLL.
Conclusions
The only known curative treatment for B-CLL is allogeneic stem cell transplantation; an effect
produced, at least in part, by the GvL activity of donor T cells. To avoid concomitant GvHD,
investigators have prepared T cells directed to TAAs that are more restricted in their tissue
distribution. The clinical use of transgenic T cells expressing B-CLL-directed receptors is in
its infancy, but as knowledge of the molecular markers of B-CLL improves and understanding
of the cellular biology of the immune system increases, this approach is likely to become
progressively more feasible and effective. It will, however, be important to ensure that these
B-CLL-specific T cells are directed towards antigens that are present in any stem or precursor
cell malignant population, and are not limited to the cells of mature tumours.
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Structure of transgenic T-cell receptors (TCRs) and chimeric antigen receptors (CARs). (A) T
lymphocytes expressing the native TCR/CD3 complex and the transgenic TCR. Two strategies
to maximize the expression of the transgenic TCR are also illustrated: in codon optimization
of the sequences of TCR-α and TCR-β; and the inclusion of a second disulphide bond
corresponding to the constant region of the TCR. (B) Schematic structure of first- and second-
generation CARs. Second-generation CARs contain one or more co-stimulatory endodomains
(illustrated with CD28), cloned in frame with the scFv and the CD3-ζ endodomain.
Foster et al. Page 13














Chimeric antigen receptor (CAR)-redirected T lymphocytes can eliminate B-cell chronic
lymphocytic leukaemia (B-CLL) cells. T-lymphocytes isolated from the peripheral blood of
B-CLL patients were transduced either with control-GFP vector, or CAR CD19-CD28ζ or
CAR κ-light-chain-CD28ζ vectors. (A) Expression of the CARs on transgenic T cells detected
by flow cytometry using an antibody recognizing the spacer region of the CARs. (B) After
transduction, T cells were co-cultured with autologous B-CLL cells expressing either κ+ or
λ+ (ratio 5:1). After 3–4 days of culture, cells were collected and stained with CD3-PerCP and
CD19-PE and analysed by flow cytometry to evaluate the growth of CD19+ B-CLL cells. No
CD19+/κ+ cells were detectable after co-culture with CAR CD19-CD28ζ or CAR κ-light-chain-
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CD28ζ T cells, while CD19+/λ+ cells were detectable when tumour cells were co-cultured with
control T cells or CAR κ-light-chain-CD28ζ T cells. This experiment illustrates that T cells
redirected to target the κ-light chain expressed on the cell surface of B-CLL can eliminate
tumour cells as efficiently as CAR CD19-redirected T cells, but also spare B cells expressing
the λ-light chain.
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B-cell chronic lymphocytic leukaemia (B-CLL) primary tumour cells contain a distinct side
population (SP) phenotype. Primary leukaemic cells isolated from the peripheral blood of B-
CLL patients were stained with Hoechst 33342 for 90 mins, and then labelled with either
isotype control antibodies or CD5 FITC and CD19 PE to distinguish B-CLL cells from normal
B cells. SP cells are CD5+CD19+ and are not present in the peripheral blood of healthy donors
(not shown).
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